I hear you but respectfully dont believe CHMs biggest issue is corporate governance.....
Unfortunately the biotech sector is at cyclical lows. Donald Trump is killing market sentiment and forcing risk off trading. A few corporate wobbles havent helped our case....
That said, I still optimistic with plenty of skin in the game. Some positive news flow and strong clinical data can send the SP into the stratosphere. I have already posted on this forum a number of examples of unloved biotech stocks going parabolic after one big announcement. That's all it takes in this game. The CHM's lead therapy, CDH17 CART, could just deliver on this front given the early efficacy signals we are seeing.
Add to My Watchlist
What is My Watchlist?
